Breakthrough Supplement Quietum Plus Targets the Neural Root of Hearing Loss With Science-Backed Brain-Ear Connection Support for Tinnitus and Age-Related Decline

Breakthrough Chewable Supplement Targets Inner Ear Balance and Dizziness Relief With Marine Minerals, Bioactive B6, and Clinically Studied Nutrients

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older

Sweeping Q1-Q2 2025 survey of nearly 12,000 managed care IT users nationwide ranks top vendors across multiple categories; Inovalon secures top honors again.

From June 17-19, Medical Component Specialists will be in Chicago for the 19th annual Orthopedic Manufacturing & Technology Exposition and Conference.

Breakthrough OTC 455-4 Certification Positions Gummi World as the First Pharmaceutical-Grade Gummy Partner in the U.S.

Herbal Tea Therapy introduces BREATHE 8-in-1 Mullein Drops - a fast-absorbing liquid lung support formula featuring mullein, peppermint, and thyme, designed to naturally aid respiratory detox and promote healthy breathing for former smokers and wellness-conscious users.

The prestigious certification places The Perfumery in the top 5% of companies globally recognized by EcoVadis for sustainability and social responsibility

Discover the truth behind Nerve Freedom's neuropathy relief claims as we investigate real user complaints, review clinical ingredients like Alpha Lipoic Acid and Turmeric, and compare long-term results, pricing, and expert recommendations for the best natural nerve pain support in 2025.

Testosil by Leading Edge Health is a clinically-backed natural testosterone booster formulated for men over 40 and 50, designed to support muscle growth, energy, mood, and intimate health by boosting testosterone up to 434% - without synthetic hormones or stimulants.

Leading Health Edge's GenuinePurity™ Liposomal NMN Emerges as the 2025 Industry Benchmark for Anti-Aging Supplements With 96%+ Purity, Superior Bioavailability, and Third-Party Verified Pharmaceutical-Grade Quality

Is it possible that a simple sound can hurt you? That the sound of a bird singing in the yard can make you scream out in pain? That's the reality of having CRPS. Here's how the Spero Clinic helped Heather get her life back.

Notable Systems continues to expand its executive team with two key appointments: Brian Nannie, former Chief Data Officer at Lincare, joins as Senior Vice President of Client Strategy & Innovation, and Gaurav Nukala, former Head of Product Operations at Innovaccer, assumes the role of Senior Vice President of Product. These strategic hires strengthen Notable's leadership team with deep expertise in DME, HME, and healthcare revenue cycle management.

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs

Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.

Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases

ATW Partners and DWF Labs invested $55 million in initial closing

TRNR is expected to have the largest US publicly listed crypto treasury focused on an AI-token

Company's Stem Cell Research Highlighted Amid National Policy Discussion on Alternative Therapies

Achieving a five-month revenue growth equivalent to an annualized rate exceeding 4,000%, as the booming CBD and mushroom supplement markets-projected to reach $30 billion and $15 billion respectively by 2028-fuel strong consumer demand and industry expansion.

~ Pain Management, RE-Invented: A New Era for Analgesia ~

In-Depth, Transparent Industry Studies Highlight Leading IT Solutions, Managed Services, Outsourcing, and Advisory Firms Serving Health Plans Since 2004; AHIP Conference to Showcase Top Vendor Recognitions

The inventor of sustained acoustic medicine and the sam® wearable ultrasound technologies support students at an internationally known summer program and funds student and professional research through its STEM Scholarship Program.

HIMSS25 Europe takes place June 10-12, 2025 at the Palais des Congrès in Paris, showcasing the latest digital health innovations and driving collaboration across the European healthcare IT ecosystem.

A culture change is affecting how people talk about cosmetic surgery, from popular TikToks to BBL reversals. Dr. Meegan Gruber shows why choices made with knowledge and power are becoming more critical.

Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025

Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses

Company's Stem Cell Research Highlighted Amid National Policy Discussion on Alternative Therapies 

DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual. 

Gross proceeds from offering total $16.6 million.

Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.

EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.

EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.

Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time.

This major update reinforces the platform's leadership in AI-assisted VR therapy, tele- and digital medicine and highly customizable mental health therapeutic experiences.

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies

The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases

Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer

A New Era of Accessible Health Monitoring

Independent Global Study Evaluates EHR Satisfaction Across 110 Countries; 93% of European Users Say Dedalus Clinical Documentation Tools Better Align with Local Workflows than U.S. Vendors

Terrance Cole's First Test: Will He Restore DEA Diversion To Legitimacy

Independent Survey Reveals Gaps in Greek Healthcare IT, Underscoring Urgent Need for Homegrown Digital Solutions and Modernization Partnerships

Ahead of Next Week's HIMSS 25 Europe in Paris, Attendees Look to Top Interoperability Vendors for Solutions

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing.

Dr. Shervin Naderi and his team integrate facial rejuvenation with weight loss care to manage the structural facial changes associated with GLP-1 medications.

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.

EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.

EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts.

EXXUA transaction financed by long-term, healthcare-focused institutional investors, including Aytu's largest shareholder Nantahala Capital Management, Stonepine Capital Management, Aytu management, and new institutional shareholders.

A recent publication by quantum researcher Ali Karakuş draws the attention of the medical industry.

Terrance Cole, the nominee for Administrator of the U.S. Drug Enforcement Administration (DEA), stands at a pivotal juncture with the opportunity to address longstanding issues related to the agency's handling of cannabis policy.

10 veterinary clinics signed up 65 pets to compete for over $10,000 in prizes and donate to 13 rescues.